- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04941248
Total-body 13N-NH3 PET/CT to Study the Blood Perfusion in Whole Body
The Application of Total-body 13N-NH3 PET/CT to Study the Blood Perfusion System in the Whole Body
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants are invited to participate in a research that seeks to understand the dynamic blood perfusion in human body. The investigators expect to have twenty-five participants in this study at Renji Hospital, Shanghai. About sixteen of the participants will be patients who have been diagnosed with decreased cardiac function, nine participants will be healthy individuals with no known vascular disease. These healthy subjects will allow researchers to compare blood perfusion difference with those of persons with decreased cardiac function. All the participants will undergo the same procedure.
If participants agree to participate in this study, researchers will first interview participants and review the past medical record in order to document the medical history. When the screening procedures confirm that participants are eligible to participate in the study, participants will receive one dose of the non-therapeutic administration of a radioactive tracer called N-13 ammonia(13NH3) , then undergo one total body 13NH3 PET/CT Scan (uEXPLORER) to determine the blood flow value of the brain, kidney and other organs. The total body 13NH3 PET/CT Scan will allow investigators to observe and analyze the real-time blood flow differences between patients with between healthy controls and decreased cardiac function.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Xiaofeng Yu
- Phone Number: 86-021-58752345
- Email: minkeyperfect@126.com
Study Contact Backup
- Name: Yumei Chen, Ph.D; M.D.
- Phone Number: 86-021-58752345
- Email: cymrenji@126.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200127
- Recruiting
- shanghai Jiaotong University School of Medicine, Renji Hospital
-
Contact:
- Yumei Chen, Ph.D;M.D.
- Phone Number: 86-021-58752345
- Email: cymrenji@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Nine healthy volunteers with normal EF values
- Patients with decreased cardiac function, while their heart function grading above II(New York Heart Association,NYHA)
- Aged 18~85 years old
- Written informed consents will be offered and signed by all participants
Exclusion Criteria:
- History of vascular-related diseases in other organs
- Severe liver and kidney dysfunctions
- Patients who are pregnant or breast feeding
- People under the age of 18 years old
- Heart function grading below II(NYHA)
- inability to lie or to maintain posture in the scanner for one hour
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy controls
All healthy subjects will undergo the following intervention: 13N-NH3 PET/CT scan on the total-body uEXPLORER scanner.
|
This prospective study will enroll twenty-five patients, including nine healthy volunteers, sixteen patients with decreased cardiac function .
All of them will have a whole-body PET/CT(uEXPLORER , United Imaging Healthcare, China) in our department, Renji Hospital.
|
Patients with decreased cardiac function
All patients will undergo the following intervention: 13N-NH3 PET/CT scan on the total-body uEXPLORER scanner.
|
This prospective study will enroll twenty-five patients, including nine healthy volunteers, sixteen patients with decreased cardiac function .
All of them will have a whole-body PET/CT(uEXPLORER , United Imaging Healthcare, China) in our department, Renji Hospital.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Multi-Organ Blood Perfusion by Total Body Dynamic uEXPLORER PET/CT Scan
Time Frame: 4 years
|
The total-body 13N-NH3 PET/CT will be adopted to evaluate the blood flow differences in whole body between healthy controls and patients with decreased cardiac function.
|
4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yumei Chen, Ph.D; M.D., Shanghai Jiaotong University School of Medicine,Renji Hospital
Publications and helpful links
General Publications
- Benz DC, Ferro P, Safa N, Messerli M, von Felten E, Huang W, Patriki D, Giannopoulos AA, Fuchs TA, Grani C, Gebhard C, Pazhenkottil AP, Kaufmann PA, Buechel RR. Role of quantitative myocardial blood flow and 13N-ammonia washout for viability assessment in ischemic cardiomyopathy. J Nucl Cardiol. 2021 Feb;28(1):263-273. doi: 10.1007/s12350-019-01684-1. Epub 2019 Mar 20.
- Lang JK, Canty JM Jr. The complexity of using resting myocardial perfusion to assess myocardial viability and predict functional recovery. J Nucl Cardiol. 2021 Feb;28(1):274-277. doi: 10.1007/s12350-019-01742-8. Epub 2019 May 13. No abstract available.
- Kang KW, Kim JS, Cho SG, Kim J, Song HC. Acquisition of dynamic N-13 ammonia PET for myocardial blood flow quantification. J Nucl Cardiol. 2020 Aug;27(4):1288-1292. doi: 10.1007/s12350-020-02062-y. Epub 2020 Feb 19. No abstract available.
- Giubbini R, Peli A, Milan E, Sciagra R, Camoni L, Albano D, Bertoli M, Bonacina M, Motta F, Statuto M, Rodella CA, De Agostini A, Calabretta R, Bertagna F; Italian Nuclear Cardiology Group (GICN). Comparison between the summed difference score and myocardial blood flow measured by 13N-ammonia. J Nucl Cardiol. 2018 Oct;25(5):1621-1628. doi: 10.1007/s12350-017-0789-z. Epub 2017 Feb 3.
- Sciagra R, Lubberink M, Hyafil F, Saraste A, Slart RHJA, Agostini D, Nappi C, Georgoulias P, Bucerius J, Rischpler C, Verberne HJ; Cardiovascular Committee of the European Association of Nuclear Medicine (EANM). EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1040-1069. doi: 10.1007/s00259-020-05046-9. Epub 2020 Nov 2.
- Lammertsma AA. Forward to the Past: The Case for Quantitative PET Imaging. J Nucl Med. 2017 Jul;58(7):1019-1024. doi: 10.2967/jnumed.116.188029. Epub 2017 May 18.
- Akamatsu G, Uba K, Taniguchi T, Mitsumoto K, Narisue A, Tsutsui Y, Sasaki M. Impact of Time-of-Flight PET/CT with a Large Axial Field of View for Reducing Whole-Body Acquisition Time. J Nucl Med Technol. 2014 Jun;42(2):101-4. doi: 10.2967/jnmt.114.140665. Epub 2014 May 5.
- Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2265-2267. doi: 10.1073/pnas.1917379117. Epub 2020 Jan 21.
- Zhang X, Xie Z, Berg E, Judenhofer MS, Liu W, Xu T, Ding Y, Lv Y, Dong Y, Deng Z, Tang S, Shi H, Hu P, Chen S, Bao J, Li H, Zhou J, Wang G, Cherry SR, Badawi RD, Qi J. Total-Body Dynamic Reconstruction and Parametric Imaging on the uEXPLORER. J Nucl Med. 2020 Feb;61(2):285-291. doi: 10.2967/jnumed.119.230565. Epub 2019 Jul 13.
- Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care. J Nucl Med. 2018 Jan;59(1):3-12. doi: 10.2967/jnumed.116.184028. Epub 2017 Sep 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- KY2021-086
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Output
-
HeartBeat Technologies LTDUnknownLow Cardiac Output | High Cardiac OutputIsrael
-
Radboud University Medical CenterRecruiting
-
University Hospital, AngersTerminated
-
The University of Texas Medical Branch, GalvestonCompletedCardiac OutputUnited States
-
Université Libre de BruxellesCompleted
-
Centre Hospitalier Universitaire de BesanconUnknown
-
University of British ColumbiaCompleted
-
Cairo UniversityCompleted
-
Transonic Systems Inc.National Heart, Lung, and Blood Institute (NHLBI)Terminated
Clinical Trials on total-body PET/CT(uEXPLORER , United Imaging Healthcare, China)
-
RenJi HospitalEnrolling by invitation
-
Sun Yat-sen UniversityCompleted
-
Rigshospitalet, DenmarkRecruiting
-
Ontario Clinical Oncology Group (OCOG)Cancer Care OntarioActive, not recruitingMuscle-invasive Bladder CancerCanada
-
University of California, DavisColorado SPORE Developmental Research ProgramActive, not recruitingHead and Neck CancerUnited States
-
RenJi HospitalCompletedPET/CT | IMAGE | Prostate Specific Membrane AntigenChina
-
University of California, DavisLantheus Medical ImagingEnrolling by invitationBreast Cancer | Prostate Cancer | Neuroendocrine TumorsUnited States
-
Jonsson Comprehensive Cancer CenterImaginAb, Inc.CompletedPancreatic Cancer | Prostate Cancer | Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; Erasmus Medical Center; University Hospital... and other collaboratorsCompletedMultiple Trauma/InjuriesNetherlands, Switzerland
-
Robert Flavell, MD, PhDUnited States Department of Defense; Fortis Therapeutics, Inc.RecruitingProstate Cancer | Metastatic Castration-resistant Prostate CancerUnited States